@article{Huang2026, 
author = {Chunxiang Huang and Keying Wang and Zhizhu Ke and Mingyu Zhang and Qiuping Huang and Chenxi Tong and Chuangzhi Yan and Zichun Song and Jiejing Xu and Tieming Jiang and Jiale Song},
title = {Sinapic acid regulated the cardiometabolic and intestinal flora disorders to attenuate the myocardial fibrosis in HFD and STZ-induced diabetic mice},
year = {2026},
journal = {Food Science and Human Wellness},
volume = {15},
number = {5},
pages = {9250466},
keywords = {Diabetes mellitus, Myocardial fibrosis, Sinapic acid, TGF-β1/Smad pathway, Nontargeted metabolomics, Intestinal flora},
url = {https://www.sciopen.com/article/10.26599/FSHW.2025.9250466},
doi = {10.26599/FSHW.2025.9250466},
abstract = {Myocardial fibrosis is a critical stage in the progression of diabetic cardiomyopathy (DCM). Sinapic acid (SA) is a plant phenolic acid compound with antimicrobial, antioxidant, and anti-inflammatory activities. To observe the effects of SA intervention on the development of myocardial fibrosis in diabetes mellitus (DM) model mice, we successfully established a DM mouse model via a high-fat diet (HFD) and streptozotocin (STZ) injection. After SA intervention for 4 weeks, we found that SA intervention significantly reduced oxidative damage, lipid metabolism disorders, and inflammatory stimuli. Furthermore, SA may decrease myocardial fibrosis in DM mice by inhibiting the activation of the TGF-β1/Smad pathway, promoting riboflavin, nicotinate, and nicotinamide metabolism, inhibiting arachidonic acid metabolism, and restoring the disruption of the intestinal flora. Our research supports the use of SA as a potential supplementary treatment option in the management of DCM.}
}